12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Emergent BioSolutions, Abbott deal

Emergent said Abbott will terminate a 2009 deal to co-develop and commercialize Emergent's cancer product TRU-016. Abbott's decision is a result of a portfolio prioritization process, according to Emergent. Until the termination becomes effective on...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >